Skip to main content

RXRX

Stock
Health Care
Biotechnology

Performance overview

RXRX Price
Price Chart

Forward-looking statistics

Beta
1.57
Risk
94.96%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Company info

SectorHealth Care
IndustryBiotechnology
Employees507
Market cap$2.0B

Fundamentals

Enterprise value$1.7B
Revenue$59.8M
Revenue per employee—
Profit margin22.65%
Debt to equity9.95

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.80
Dividend per share—
Revenue per share$0.19
Avg trading volume (30 day)$151M
Avg trading volume (10 day)$142M
Put-call ratio—

Macro factor sensitivity

Growth+0.4
Credit+8.0
Liquidity-4.7
Inflation-2.3
Commodities-0.6
Interest Rates-3.1

Valuation

Dividend yield0.00%
PEG Ratio-3.05
Price to sales35.83
P/E Ratio-3.05
Enterprise Value to Revenue27.62
Price to book2.29

Upcoming events

Next earnings dayMay 5, 2025
Next dividend day—
Ex. dividend day—

News

Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $5.72, marking a +2.24% move from the previous day.

Zacks Investment Research (July 10, 2025)
What's Happening With RXRX Stock?

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this underperformance, the clinical-stage TechBio firm continues to attract interest for its innovative approach to drug discovery driven by AI and machine learning.

Forbes (July 8, 2025)
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Recursion Pharmaceuticals Inc RXRX is a leader in the TechBio space "due to its broad capabilities and extensive internal data generation," according to Needham.

Benzinga (March 3, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free